Alimera Sciences, Inc. (ALIM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALIM POWR Grades
- ALIM scores best on the Value dimension, with a Value rank ahead of 89.66% of US stocks.
- The strongest trend for ALIM is in Momentum, which has been heading down over the past 31 weeks.
- ALIM's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
ALIM Stock Summary
- With a market capitalization of $71,090,970, Alimera Sciences Inc has a greater market value than merely 11.29% of US stocks.
- Alimera Sciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 2.41% of US listed stocks.
- ALIM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 2.66% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Alimera Sciences Inc are USWS, XTNT, UIS, CMPR, and STAF.
- ALIM's SEC filings can be seen here. And to visit Alimera Sciences Inc's official web site, go to www.alimerasciences.com.
ALIM Stock Price Chart Interactive Chart >
ALIM Price/Volume Stats
|Current price||$10.30||52-week high||$12.25|
|Prev. close||$10.38||52-week low||$3.82|
|Day high||$10.50||Avg. volume||68,577|
|50-day MA||$9.92||Dividend yield||N/A|
|200-day MA||$7.10||Market Cap||71.23M|
Alimera Sciences, Inc. (ALIM) Company Bio
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
ALIM Latest News Stream
|Loading, please wait...|
ALIM Latest Social Stream
View Full ALIM Social Stream
Latest ALIM News From Around the Web
Below are the latest news stories about Alimera Sciences Inc that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Summer Solstice - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, June 1, 2021, with company presentations beginning at 9am Eastern Time.
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021. Rick Eiswirth, President and Chief Executive Officer will deliver his corporate presentation on June 2, 2021 at 10:30am ET. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2134/41505 To receive additional information, request an invitation, please email [email protected] Investors can register here. About the MicroCap Rode...
Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years
Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence Amid required stay-at-home orders, many have paused or canceled doctor’s appointments over the past 12 months. Recent studies show some of the troubling effects of patients missing out on treatments for vision loss. Alimera Sciences believes it has a solution. A Daily Microdose Recently, the Cleveland Clinic published a paper, “The Effect of Delay in Care Among Patients Requiring Intravitreal Injections,” regarding the results of patients missing their prescribed vision loss treatments due to the COVID pandemic. This 1,041-patient retrospective analysis examined the effect of a delay in care on the visual acuity of patients requiring intravitreal injections. The authors looked at patients with retina di...
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
Conference Call to be held Thursday, April 29, 2021 at 9:00am Eastern TimeATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report first quarter 2021 financial results on Wednesday, April 28, 2021 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, April 29, 2021 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session. Participants are asked to pre-register for the call. Please note that registered participan...
ALIM Price Returns